semaglutide shortness of breath GLP-1s Semaglutide Weight Loss Treatment: GLP-1

This series of phase 3, randomised, double-blind, placebo-controlled clinical trials involved more than 25,000 individuals with overweight or obesity and has extensively demonstrated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss [13, 3846]

The condition isn't just a result of aging

Our weight loss program in San Francisco, California does prescribe weight loss medications to patients who we feel can benefit from them

Current standard of care for obesity-related KOA is: NSAIDs (symptom relief, doesn't address the cause, significant GI/cardiovascular risks long-term) Corticosteroid injections (short-term, diminishing returns, potential cartilage damage with repeated use) Hyaluronic acid injections (evidence is mixed, effects modest) Physical therapy (beneficial but limited when weight load isn't addressed) Total knee replacement (effective but major surgery, significant recovery, not without long-term complications) Retatrutide at TRIUMPH-4 doses addresses both the cause (adiposity, inflammation) and the symptoms (pain), with a safety profile that compares favorably to chronic NSAID use or surgical intervention

almost 40% of people deal with it